JP6444688B2 - Swelling suppression or improvement agent - Google Patents
Swelling suppression or improvement agent Download PDFInfo
- Publication number
- JP6444688B2 JP6444688B2 JP2014211330A JP2014211330A JP6444688B2 JP 6444688 B2 JP6444688 B2 JP 6444688B2 JP 2014211330 A JP2014211330 A JP 2014211330A JP 2014211330 A JP2014211330 A JP 2014211330A JP 6444688 B2 JP6444688 B2 JP 6444688B2
- Authority
- JP
- Japan
- Prior art keywords
- swelling
- seed coat
- soybean seed
- extract
- black soybean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000008961 swelling Effects 0.000 title claims description 71
- 230000006872 improvement Effects 0.000 title claims description 16
- 230000001629 suppression Effects 0.000 title description 16
- 244000068988 Glycine max Species 0.000 claims description 81
- 235000010469 Glycine max Nutrition 0.000 claims description 81
- 239000000284 extract Substances 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 49
- 239000000654 additive Substances 0.000 claims description 31
- 230000000996 additive effect Effects 0.000 claims description 29
- 230000002378 acidificating effect Effects 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 235000013305 food Nutrition 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 10
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 210000003141 lower extremity Anatomy 0.000 description 24
- 239000000843 powder Substances 0.000 description 23
- 239000002775 capsule Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 239000007788 liquid Substances 0.000 description 17
- 239000003826 tablet Substances 0.000 description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 239000002253 acid Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 210000003127 knee Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000002579 anti-swelling effect Effects 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 239000003021 water soluble solvent Substances 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 239000000469 ethanolic extract Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- 229920001353 Dextrin Polymers 0.000 description 7
- 239000004375 Dextrin Substances 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 235000019425 dextrin Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 235000015110 jellies Nutrition 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 5
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 4
- 229940092714 benzenesulfonic acid Drugs 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940032330 sulfuric acid Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004503 fine granule Substances 0.000 description 2
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101000856234 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) Butyrate-acetoacetate CoA-transferase subunit A Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000002816 chronic venous insufficiency Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical class C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000010729 leg swelling Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- -1 troches Substances 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Beans For Foods Or Fodder (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、身体局所のむくみ、特に下肢部のむくみを抑制または改善する効果を有する可食性組成物に関する。当該可食性組成物は、それ自体、経口医薬品、経口医薬部外品、及び飲食物として使用されるほか、むくみ抑制または改善を効能・効果とする経口医薬品、経口医薬部外品、及び飲食物を製造するための添加物として使用することができる。 The present invention relates to an edible composition having an effect of suppressing or improving swelling of a local body, particularly swelling of a lower limb. The edible composition itself is used as an oral drug, an oral quasi-drug, and a food and drink, as well as an oral drug, oral quasi-drug, and food and drink with the effect of suppressing or improving swelling. Can be used as an additive for the production.
長時間の立位や座位などによって発生する自然発生的な身体局所のむくみ、特に下肢部のむくみは、靴が履き難くなるなど日常活動に支障が生じるといった問題のほか、だるさ、重さ、つっぱり感、痛みなどの不快感(身体的不調)を伴う場合もある。またむくみ(血管性むくみ)が慢性化すると慢性静脈不全になりやすくなったり、さらにこれが重症化すると、静脈瘤、下肢の皮膚の褐色調変色、または下肢の皮膚潰瘍などを招く場合があるとされている。 Spontaneous swelling of the body caused by standing or sitting for a long time, especially swelling of the lower limbs, may cause problems with daily activities such as difficulty in wearing shoes, as well as dullness, weight, and tension It may be accompanied by discomfort (physical disorder) such as feeling and pain. If swelling (vascular swelling) becomes chronic, chronic venous insufficiency tends to occur, and if this becomes more severe, it may lead to varicose veins, brown discoloration of the skin of the lower limbs, or skin ulcers of the lower limbs. ing.
このような身体局所、特に下肢部のむくみ(血管性むくみ)は、立位や座位などによる毛細血管の静水圧の上昇により、毛細血管から細胞間質に体液が漏出し。さらに細胞の水分代謝が停滞することで体液回収のバランスが崩れ、細胞間質に体液が停滞することが主な原因と考えられている。具体的には、立位や座位が長く続くと、足の筋ポンプが機能しなくなり、そのため血液が心臓にむかって流れる血流は停滞する。このとき、血液自体の重量が静脈内にかかるため、静脈圧(静脈内の圧力)が上昇し、静脈が拡張した状態となり、当該静脈の拡張により、静脈内の血液は下肢に溜まりやすくなる。このように、下肢で静脈環流が滞ると、下肢静脈内の圧力が上昇するため、血管内から血管外へ血液の血漿成分(水分)が滲み出て、細胞外に水分が貯留する。これが下肢部のむくみの原因である。 Such body swelling, particularly swelling of the lower limbs (vascular swelling), leaks body fluid from the capillaries to the cell stroma due to increased hydrostatic pressure of the capillaries due to standing or sitting. Further, the stagnation of water metabolism in cells causes the balance of body fluid recovery to be lost, and it is considered that the body fluid is stagnated in the cell stroma. Specifically, if the standing or sitting position continues for a long time, the foot muscle pump does not function, so that the blood flow that flows toward the heart stagnate. At this time, since the weight of the blood itself is applied to the vein, the venous pressure (intravenous pressure) increases and the vein expands, and the expansion of the vein makes it easier for blood in the vein to accumulate in the lower limbs. As described above, when the venous circulation is stagnated in the lower limbs, the pressure in the lower limb veins rises, so that blood plasma components (water) exude from the blood vessels to the outside of the blood vessels, and the water is stored outside the cells. This is the cause of swelling of the lower limbs.
むくみの改善方法としては、従来から、靴下やストッキングで足を適度に締め付ける方法のほか、足温器や足マッサ−ジ器などを利用して体外から刺激を与える方法が提案されている。また飲食物等の可食性組成物を服用(摂取)する方法としては、ヒハツを有効成分とするむくみ感改善剤(特許文献1)、α−グルコシル化ヘスペリジンを有効成分とするむくみ改善剤(特許文献2)、及びロイシン、イソロイシン及びバリンを含有するむくみの予防又は改善用食品組成物(特許文献3)などが提案されている。 Conventionally, as a method for improving swelling, a method of giving a stimulus from outside the body using a foot warmer, a foot massager, or the like has been proposed in addition to a method of appropriately tightening a foot with socks or stockings. Moreover, as a method of taking (ingesting) an edible composition such as food and drink, a swelling improving agent containing Japanese red pepper as an active ingredient (Patent Document 1), a swelling improving agent containing α-glucosylated hesperidin as an active ingredient (patent) Document 2), and a food composition for preventing or improving swelling containing leucine, isoleucine and valine (Patent Document 3) have been proposed.
本発明は、むくみ、特に下肢部のむくみを抑制または改善する効果を発揮する可食性組成物を提供することを目的とする。より具体的には、本発明は当該可食性組成物を、経口投与(または経口摂取)により使用される「むくみ抑制または改善剤」として、また経口投与(または経口摂取)される経口組成物に、むくみ抑制または改善作用を付加するために用いられる添加剤、つまり「むくみ抑制または改善用の経口組成物用添加剤」として提供することを目的とする。 An object of this invention is to provide the edible composition which exhibits the effect which suppresses or improves swelling, especially the swelling of a leg part. More specifically, the present invention relates to an edible composition as an “swelling suppressing or ameliorating agent” used by oral administration (or oral ingestion) and an oral composition to be administered orally (or oral ingestion). An object of the present invention is to provide an additive used for adding an effect of suppressing or improving swelling, that is, an “additive for oral composition for suppressing or improving swelling”.
本発明者らは、上記目的を解決すべく鋭意検討を重ねていたところ、黒大豆種皮抽出物、特に黒大豆種皮の酸性抽出物に優れたむくみ抑制または改善作用があることを見出し、さらに研究を重ねることによって本発明を完成するに至った。 The inventors of the present invention have made extensive studies to solve the above-mentioned object, and found that black soybean seed coat extract, particularly acidic extract of black soybean seed coat has excellent swelling suppression or improvement action, and further research. As a result, the present invention was completed.
本発明は、下記の実施形態を有するものである。
(I)むくみ抑制または改善剤
I−1.黒大豆種皮抽出物を有効成分とするむくみ抑制または改善剤。
I−2.黒大豆種皮加工物が黒大豆種皮の酸性抽出物である、I−1記載のむくみ抑制または改善剤。
I−3.上記酸性抽出物が、黒大豆種皮からスルホ基含有酸を含む溶媒を用いて抽出された組成物である、I−2記載のむくみ抑制または改善剤。
I−4.スルホ基含有酸が、硫酸、メタンスルホン酸、ベンゼンスルホン酸、p−トルエンスルホ酸、及び10−カンファースルホン酸からなる群から選択される少なくとも1種である、I−3記載のむくみ抑制または改善剤。
I−5.上記抽出物が、黒大豆種皮を加温条件下、30℃以上、好ましくは50℃以上、より好ましくは50〜80℃の条件下で抽出して得られたものである、I−1〜I−4のいずれかに記載するむくみ抑制または改善剤。
I−6.経口投与形態を有するものであるI−1〜I−5のいずれかに記載するむくみ抑制または改善剤。
I−7.錠剤、丸剤、カプセル剤(硬質カプセル、軟質カプセル)、散剤、顆粒剤、トロ−チ錠、液剤、及びゼリー剤から選択される製剤形態を有する、I−1〜I−6のいずれかに記載するむくみ抑制または改善剤。
I−8.飲食物、好ましくは水または清涼水と組み合わせて使用されるI−1〜I−7のいずれかに記載するむくみ抑制または改善剤。
The present invention has the following embodiments.
(I) Swelling suppressing or improving agent 1-1 . A swelling suppression or improvement agent comprising black soybean seed coat extract as an active ingredient.
I-2. The swelling inhibiting or improving agent according to I-1, wherein the processed black soybean seed coat is an acidic extract of black soybean seed coat.
I-3. The swelling control or improvement agent according to I-2, wherein the acidic extract is a composition extracted from black soybean seed coat using a solvent containing a sulfo group-containing acid.
I-4. The swelling suppression or improvement according to I-3, wherein the sulfo group-containing acid is at least one selected from the group consisting of sulfuric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and 10-camphorsulfonic acid. Agent.
I-5. The extract is obtained by extracting black soybean seed coats under heating conditions at 30 ° C or higher, preferably 50 ° C or higher, more preferably 50-80 ° C, I-1 to I The swelling suppression or improvement agent in any one of -4.
I-6. The swelling suppressing or improving agent according to any one of I-1 to I-5, which has an oral dosage form.
I-7. One of I-1 to I-6 having a pharmaceutical form selected from tablets, pills, capsules (hard capsules, soft capsules), powders, granules, troche tablets, liquids, and jellys The swelling suppression or improvement agent to describe.
I-8. The swelling suppression or improvement agent described in any of I-1 to I-7 used in combination with food and drink, preferably water or fresh water.
(II)むくみ抑制または改善用の経口組成物用添加剤
II−1.黒大豆種皮抽出物を有効成分とするむくみ抑制または改善用の経口組成物用添加剤。
II−2.黒大豆種皮抽出物が黒大豆種皮の酸性抽出物である、II−1記載の経口組成物用添加剤。
II−3.上記酸性抽出物が、黒大豆種皮からスルホ基含有酸を含む溶媒を用いて抽出された組成物である、II−2記載の経口組成物用添加剤。
II−4.スルホ基含有酸が、硫酸、メタンスルホン酸、ベンゼンスルホン酸、p−トルエンスルホ酸、及び10−カンファースルホン酸からなる群から選択される少なくとも1種である、II−3記載の経口組成物用添加剤。
II−5.上記抽出物が、黒大豆種皮を加温条件下、30℃以上、好ましくは50℃以上、より好ましくは50〜80℃の条件下で抽出して得られたものである、II−1〜II−4のいずれかに記載する経口組成物用添加剤。
II−6.飲食品用の添加剤であるII−1〜II−5のいずれかに記載する経口組成物用添加剤。
II−7.錠剤、丸剤、カプセル剤(硬質カプセル、軟質カプセル)、散剤、顆粒剤、トロ−チ錠、液剤、及びゼリー剤から選択される製剤形態を有する、II−1〜II−6のいずれかに記載する経口組成物用添加剤。
(II) Additives for oral compositions for suppressing or improving swelling
II-1. An additive for oral composition for suppressing or improving swelling, comprising black soybean seed coat extract as an active ingredient.
II-2. The additive for oral compositions according to II-1, wherein the black soybean seed coat extract is an acidic extract of black soybean seed coat.
II-3. The additive for oral compositions according to II-2, wherein the acidic extract is a composition extracted from black soybean seed coat using a solvent containing a sulfo group-containing acid.
II-4. The oral composition according to II-3, wherein the sulfo group-containing acid is at least one selected from the group consisting of sulfuric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and 10-camphorsulfonic acid. Additive.
II-5. II-1 to II, wherein the extract is obtained by extracting black soybean seed coats under warming conditions at 30 ° C or higher, preferably 50 ° C or higher, more preferably 50-80 ° C. The additive for oral compositions as described in any of -4.
II-6. An additive for oral composition according to any one of II-1 to II-5, which is an additive for food and drink.
II-7. Any one of II-1 to II-6 having a pharmaceutical form selected from tablets, pills, capsules (hard capsules, soft capsules), powders, granules, troches, liquids, and jellys Additives for oral compositions to be described.
本発明のむくみ抑制または改善剤によれば、長時間の立居や座位等によって生じる身体局所、特に下肢部のむくみを抑制するかまた改善することができる。また本発明のむくみ抑制または改善用の経口組成物用添加剤は、経口組成物に対してむくみ抑制または改善作用を付与または強化するために用いることができる。つまり、本発明の添加剤は、むくみ抑制または改善用の経口組成物の調製に使用することができ、斯くして、長時間の立居や座位等によって生じる身体局所、特に下肢部のむくみを抑制するかまた改善する効果に優れたむくみ抑制または改善用経口組成物(経口医薬品、経口医薬部外品、飲食品)を調製し、提供することができる。 According to the swelling suppressing or improving agent of the present invention, it is possible to suppress or improve the swelling of the body, particularly the lower limbs, caused by standing or sitting for a long time. Further, the additive for oral composition for suppressing or improving swelling of the present invention can be used for imparting or enhancing swelling effect or improving action to the oral composition. That is, the additive of the present invention can be used for the preparation of an oral composition for suppressing or improving swelling, and thus suppresses local swelling, particularly lower leg swelling caused by standing or sitting for a long time. It is also possible to prepare and provide an oral composition (oral medicine, oral quasi-drug, food and drink) for suppressing or improving swelling, which has an excellent effect of improving.
(1)むくみ抑制または改善剤
本発明のむくみ抑制または改善剤は、黒大豆種皮の抽出物、好ましくは可食性の抽出物を有効成分とすることを特徴とする。
(1) Swelling inhibiting or improving agent The swelling inhibiting or improving agent of the present invention is characterized by containing an extract of black soybean seed coat, preferably an edible extract as an active ingredient.
本発明において用いられる黒大豆とは、マメ科ダイズ属Glycine max(L.)Merrillに属する短日性の一年生草木の黒い種子(子実)(黒大豆)である。黒大豆には、例えば中生光黒、トカチクロ、いわいくろ、玉大黒、丹波黒、信濃黒及び雁喰などの品種があるが、黒大豆であればどの品種の種子を使用しても良い。 The black soybean used in the present invention is a black seed (grain) (black soybean) of a short-day annual plant belonging to the leguminous soybean genus Glycine max (L.) Merrill . Examples of black soybean include varieties such as Meiko Koguro, Tokachikuro, Iwakuro, Tamadakuro, Tamba Black, Shinano Black, and Goku, but seeds of any variety may be used as long as they are black soybeans.
黒大豆を、例えば分別機等に供することで種皮と胚(子葉および胚軸)とに分別することができる。本発明では当該分別により得られる黒大豆の種皮を加工原料として使用することができる。加工処理に際して、黒大豆の種皮は、分別したそのままの状態(生または乾燥物)のものであっても、またそれを破砕若しくは粉砕した状態のもの(破砕物、粉砕物、及び粉末状物を含む)であってもよい。 Black soybeans can be separated into seed coats and embryos (cotyledons and hypocotyls) by using, for example, a sorter. In the present invention, black soybean seed coat obtained by the fractionation can be used as a processing raw material. During processing, the seed coat of black soybeans may be in a state as it is separated (raw or dried product), or in a state in which it is crushed or crushed (crushed product, pulverized product, and powdered product) May be included).
黒大豆種皮からの抽出方法としては、一般に用いられる方法を利用することができる。制限はされないが、例えば水溶性溶媒中に生または乾燥処理した黒大豆種皮(そのままの形状、若しくは粗末、細切、破砕、粉砕状)を浸漬する方法;必要に応じて攪拌しながら抽出する方法;またはパーコレーション法等を挙げることができる。抽出に使用する温度条件は、特に制限されず、低温、常温、加温条件(高温を含む)のいずれの条件でもよいが、好ましくは加温条件(高温を含む)である。より具体的には、後述の含水低級アルコールで抽出する場合は30℃以上、好ましくは40℃〜60℃の範囲であり、制限されないものの、かかる温度条件での抽出を60分以上、好ましくは90分〜120分程度行なう。また、酸性水溶液で抽出する場合は、50℃以上、好ましくは50〜80℃の範囲であり、制限されないものの、かかる温度条件での抽出を10分以上、好ましくは20分〜120分程度行う。 As an extraction method from black soybean seed coat, a generally used method can be used. Although not limited, for example, a method of immersing raw or dried black soybean seed coat (as it is, or coarsely, chopped, crushed, ground) in a water-soluble solvent; a method of extracting with stirring as necessary Or a percolation method. The temperature conditions used for the extraction are not particularly limited, and may be any of low temperature, normal temperature, and heating conditions (including high temperature), but preferably heating conditions (including high temperature). More specifically, in the case of extraction with the below-mentioned hydrous lower alcohol, it is 30 ° C. or higher, preferably in the range of 40 ° C. to 60 ° C., and although not limited, extraction under such temperature conditions is 60 minutes or longer, preferably 90 Perform for about 120 minutes. Moreover, when extracting with acidic aqueous solution, it is 50 degreeC or more, Preferably it is the range of 50-80 degreeC, Although it does not restrict | limit, it extracts for 10 minutes or more, Preferably about 20 minutes-120 minutes are performed.
抽出に使用する水溶性溶媒としては、特に制限されないが、水、低級アルコール、またはこれらの混合物を挙げることができる。低級アルコールとしては、メタノール、エタノール、プロパノール及びイソプロピルアルコール、ブタノール等の炭素数1〜4の低級アルコールを例示することができる。低級アルコールとして好ましくはエタノールを挙げることができる。水溶性溶媒として好ましくは、水、または含水低級アルコール(特に含水エタノール)であり、より好ましくは水である。尚、含水低級アルコールを溶媒として使用する場合、それに含まれる低級アルコール量は80容量%以下であることが好ましい。 Although it does not restrict | limit especially as a water-soluble solvent used for extraction, Water, a lower alcohol, or a mixture thereof can be mentioned. Examples of lower alcohols include C1-C4 lower alcohols such as methanol, ethanol, propanol, isopropyl alcohol, and butanol. Preferred examples of the lower alcohol include ethanol. The water-soluble solvent is preferably water or water-containing lower alcohol (particularly water-containing ethanol), more preferably water. In addition, when using a hydrous lower alcohol as a solvent, it is preferable that the amount of lower alcohol contained in it is 80 volume% or less.
抽出に使用する水溶性溶媒は酸性に調整されていることが好ましい。特に制限されないが、水溶性溶媒のpH範囲は、好ましくはpH1〜4程度の範囲であり、特にpH1〜2の範囲であることが好ましい。水溶性溶媒のpHを、かかる範囲になるように調整するため、通常、有機酸や無機酸などの適当な酸性物質を用いることができる。 The water-soluble solvent used for extraction is preferably adjusted to be acidic. Although not particularly limited, the pH range of the water-soluble solvent is preferably in the range of about pH 1-4, and particularly preferably in the range of pH 1-2. In order to adjust the pH of the water-soluble solvent to be in such a range, an appropriate acidic substance such as an organic acid or an inorganic acid can be usually used.
酸性物質として、具体的には、塩酸、硫酸、硝酸、リン酸、ホウ酸などの無機酸;並びにメタンスルホン酸、ベンゼンスルホン酸、p−トルエンスルホン酸、10−カンファースフホン酸、フルオロスルホン酸(以上、スルホン酸)、ギ酸、酢酸、クエン酸、シュウ酸(以上、カルボン酸)などの有機酸を挙げることができる。好ましくはスルホ基を有する酸であり、具体的には硫酸、メタンスルホン酸、ベンゼンスルホン酸、p−トルエンスルホン酸、10−カンファースフホン酸、及びフルオロスルホン酸を挙げることができる。中でも好ましくは硫酸である。なお、水溶性溶媒における酸の規定度は、水溶性溶媒が上記pH範囲になるような範囲であれば特に制限されないものの、好ましくは0.01〜0.5Nの範囲、より好ましくは0.03〜0.5Nの範囲である。 Specific examples of the acidic substance include inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, and boric acid; and methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 10-camphorsphonic acid, and fluorosulfonic acid. Examples of the organic acid include sulfonic acid (for example, sulfonic acid), formic acid, acetic acid, citric acid, and oxalic acid (for the carboxylic acid). Preferred are acids having a sulfo group, and specific examples thereof include sulfuric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 10-camphor sulfonic acid, and fluorosulfonic acid. Of these, sulfuric acid is preferred. The normality of the acid in the water-soluble solvent is not particularly limited as long as the water-soluble solvent is in the above pH range, but is preferably in the range of 0.01 to 0.5 N, more preferably 0.03. It is in the range of ~ 0.5N.
本発明の効果を奏することを限度として、得られた抽出液に対し、必要に応じて、さらにろ過、共沈または遠心分離による固形物の除去、抽出処理、吸着処理等の精製処理を行ってもよい。 To the extent that the effects of the present invention can be achieved, the obtained extract is further subjected to purification treatment such as filtration, coprecipitation or centrifugation to remove solids, extraction treatment, adsorption treatment, etc., as necessary. Also good.
斯くして調製される黒大豆種皮抽出物は、本発明の効果を奏することを限度として、さらに必要に応じて、UHT殺菌、レトルト殺菌処理といった公知の方法による殺菌処理を行ってもよい。 The black soybean seed coat extract thus prepared may be further sterilized by a known method such as UHT sterilization or retort sterilization, if necessary, as long as the effects of the present invention are exhibited.
本発明のむくみ抑制または改善剤は、経口投与形態であれば、その形態を特に問わない。また経口投与(経口摂取)形態を有するものである限り、その用途の別(医薬品、医薬部外品、飲食物[特定保健用食品や栄養機能性食品などの保健機能性食品やサプリメントを含む])は、特に制限されるものではない。 The swelling suppressing or improving agent of the present invention is not particularly limited as long as it is an oral administration form. Moreover, as long as it has an oral administration (oral intake) form, it is classified according to its use (pharmaceuticals, quasi-drugs, foods and drinks [including health functional foods and supplements such as foods for specified health use and nutritional functional foods] ) Is not particularly limited.
経口投与形態として、具体的には、上記抽出方法により調製される抽出液を液剤(エキス形態やシロップを含む)またはゼリー剤の形態に調製したもの;抽出液を常法により粉末状または顆粒状に製剤化した散剤、細粒剤、または顆粒剤;液剤や散剤または顆粒剤をカプセルに充填したカプセル剤(硬質カプセル剤、軟質カプセル剤);または粉末または顆粒をさらに打錠して錠剤形態としたものなどを挙げることができる(固形製剤)。 As an oral dosage form, specifically, an extract prepared by the above extraction method is prepared in the form of a liquid (including extract form and syrup) or jelly; the extract is powdered or granulated by a conventional method A powder, fine granule, or granule formulated into a capsule; a capsule filled with a liquid, powder, or granule (hard capsule, soft capsule); or a powder or granule is further compressed into a tablet form (Solid preparation).
本発明のむくみ抑制または改善剤は、上記黒大豆種皮抽出物と薬学的にまたは食品として許容される従来公知の可食性の担体、賦形剤等を組み合わせて各種剤型(経口投与形態)に調製することもできる。 The swelling suppression or improvement agent of the present invention is a combination of the black soybean seed coat extract and a pharmaceutically or food-acceptable edible carrier, excipient, etc., which are combined into various dosage forms (oral dosage forms). It can also be prepared.
本発明のむくみ抑制または改善剤を液状製剤の形態とする場合、凍結保存することもでき、また凍結乾燥等により水分を除去して保存してもよい。凍結乾燥製剤やドライシロップ等は、使用時に滅菌水等を加え、再度溶解して使用される。 When the swelling suppressing or improving agent of the present invention is in the form of a liquid preparation, it can be stored frozen, or it may be stored after removing moisture by freeze drying or the like. Freeze-dried preparations, dry syrups and the like are used by adding sterilized water and dissolving them again at the time of use.
本発明のむくみ抑制または改善剤を固形剤の形態とする場合、例えば、錠剤の場合であれば、担体として当該分野で従来公知のものを広く使用することができる。このような担体としては、例えば乳糖、白糖、塩化ナトリウム、ブドウ糖、尿素、デンプン、炭酸カルシウム、カオリン、ケイ酸等の賦形剤;水、エタノール、プロパノール、単シロップ、ブドウ糖液、デンプン液、ゼラチン溶液、カルボキシメチルセルロース、セラック、メチルセルロース、リン酸カリウム、ポリビニルピロリドン、結晶セルロース、ヒドロキシプロピルセルロース、ヒプロメロース、アルギン酸ナトリウム等の結合剤;乾燥デンプン、カンテン末、ラミナラン末、炭酸水素ナトリウム、ポリオキシエチレンソルビタン脂肪酸エステル類、ラウリル硫酸ナトリウム、ステアリン酸モノグリセリド、デンプン、クロスポビドン、ポビドン、低置換度ヒドロキシプロピルセルロース等の崩壊剤;ステアリン、カカオバター、水素添加油等の崩壊抑制剤;第4級アンモニウム塩、ラウリル硫酸ナトリウム等の吸収促進剤;グリセリン等の保湿剤;デンプン、乳糖、カオリン、ベントナイト、コロイド状ケイ酸等の吸着剤;精製タルク、ステアリン酸塩、ホウ酸末、ポリエチレングリコール等の滑沢剤等を使用できる。さらに錠剤は、必要に応じ通常の剤皮を施した錠剤、例えば糖衣錠、ゼラチン被包錠、腸溶被錠、フィルムコーティング錠あるいは二重錠、多層錠とすることができる。また、前記有効成分を含有する組成物を、ゼラチン、プルラン、デンプン、アラビアガム、ヒドロキシプロピルメチルセルロース(HPMC)等を原料とする従来公知のカプセルに充填して、カプセル剤とすることができる。 When the swelling suppressing or improving agent of the present invention is in the form of a solid agent, for example, in the case of a tablet, conventionally known carriers can be widely used as carriers. Examples of such carriers include excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, and silicic acid; water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin Binders such as solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, crystalline cellulose, hydroxypropylcellulose, hypromellose, sodium alginate; dry starch, agar powder, laminaran powder, sodium bicarbonate, polyoxyethylene sorbitan fatty acid Disintegrants such as esters, sodium lauryl sulfate, monoglyceride stearate, starch, crospovidone, povidone, low-substituted hydroxypropylcellulose; stearin, cocoa butter, water Disintegration inhibitors such as additive oils; Absorption accelerators such as quaternary ammonium salts and sodium lauryl sulfate; Moisturizers such as glycerin; Adsorbents such as starch, lactose, kaolin, bentonite and colloidal silicic acid; Purified talc and stearin Lubricants such as acid salts, boric acid powder and polyethylene glycol can be used. Further, the tablets can be made into tablets with ordinary coatings as necessary, for example, sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double tablets, and multilayer tablets. Moreover, the composition containing the said active ingredient can be filled into the conventionally well-known capsule which uses gelatin, a pullulan, starch, gum arabic, hydroxypropyl methylcellulose (HPMC), etc. as a raw material, and can be set as a capsule.
また、丸剤の形態とする場合、担体として当該分野で従来公知のものを広く使用できる。その例としては、例えばブドウ糖、乳糖、デンプン、カカオ脂、硬化植物油、カオリン、タルク等の賦形剤、アラビアゴム末、トラガント末、ゼラチン、エタノール等の結合剤、ラミナラン、カンテン等の崩壊剤等を使用できる。 Moreover, when it is set as the form of a pill, a conventionally well-known thing can be widely used as a support | carrier in the said field | area. Examples include excipients such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin and talc, binders such as gum arabic powder, tragacanth powder, gelatin, ethanol, and disintegrants such as laminaran and agar. Can be used.
上記以外に、添加剤として、例えば、界面活性剤、吸収促進剤、吸着剤、充填剤、防腐剤、安定剤、乳化剤、可溶化剤など、製剤の形態に応じて適宜選択し使用することができる。 In addition to the above, as an additive, for example, a surfactant, an absorption accelerator, an adsorbent, a filler, a preservative, a stabilizer, an emulsifier, a solubilizer, and the like may be appropriately selected and used depending on the form of the preparation. it can.
これらの形態はいずれも当該分野における通常の方法を用いて調製でき、例えば、錠剤は、上記有効成分とその他錠剤を得るために必要な賦形剤等を適宜添加し、よく混合分散させたのち打錠して得ることができる。また、散剤は、上記有効成分とその他散剤を得る為に必要な賦形剤等を適宜添加し、好適な方法にて混合、粉体化して得ることができる。 Any of these forms can be prepared by using ordinary methods in the field. For example, tablets are mixed with the above active ingredients and other excipients necessary for obtaining tablets as appropriate, and mixed and dispersed well. Can be obtained by tableting. The powder can be obtained by appropriately adding the above-mentioned active ingredients and other excipients necessary for obtaining the powder, and mixing and powdering by a suitable method.
本発明のむくみ抑制または改善剤の投与量(摂取量)は、被験者の状態や症状の程度によって適宜変更され得るが、成人一人(体重50kg)に対する1日あたりの投与量(摂取量)は、当該むくみ抑制または改善剤に含まれる黒大豆種皮抽出物(乾燥量)の量に換算して通常40〜160mg程度である。通常一日1回または2〜3回に分けて経口投与の形態で用いられる。服用時刻は、特に限定されないが、朝、または長時間立位または座位する前が好ましい。また食前または食間が好ましい。 The dose (intake) of the swelling suppression or ameliorating agent of the present invention can be appropriately changed according to the condition of the subject and the degree of symptoms, but the daily dose (intake) for one adult (body weight 50 kg) is: The amount is usually about 40 to 160 mg in terms of the amount of black soybean seed coat extract (dry amount) contained in the swelling suppression or improving agent. It is usually used in the form of oral administration once a day or divided into 2 to 3 times a day. The dosing time is not particularly limited, but is preferably in the morning or before standing or sitting for a long time. Moreover, before a meal or between meals is preferable.
本発明のむくみ抑制または改善剤は、むくみ、特に下肢部にむくみを生じやすい人に対して広く適用することができる。下肢部にむくみを生じやすいか否かは、後述する実験例1に従って評価することができ、具体的には、朝と夕方とで下肢部の体積を測定比較し、夕方測定した下肢部の体積が朝測定した下肢部の体積よりも大きい場合(体積比[夕方の下肢部体積/朝の下肢部体積]が1を超える場合)をむくみを生じやすいと判断することができる。この体積比が大きいほど、むくみを生じる程度が大きいことになる。 The swelling suppressing or improving agent of the present invention can be widely applied to people who are prone to swelling, particularly swelling in the lower limbs. Whether or not swelling is likely to occur in the lower limbs can be evaluated according to Experimental Example 1 described later. Specifically, the volume of the lower limbs was measured in the morning and evening, and the volume of the lower limbs measured in the evening was measured. Is larger than the volume of the lower limb measured in the morning (when the volume ratio [lower limb volume in the evening / lower limb volume in the morning] exceeds 1), it can be determined that swelling is likely to occur. The greater the volume ratio, the greater the degree of swelling.
なお、「むくみ」は、浮腫と同義で用いられ、組織液又はリンパ液がなんらかの原因によって細胞内、細胞間隙、又は体腔内に貯留した状態であり、皮下組織においてみられる。特に本発明が対象とする「むくみ」は日常生活における立位や座位により生じる自然発生的なむくみであり、拘束はされないが、毛細血管からの体液の漏出と静脈及びリンパ系による体液の回収とのバランスが損なわれた場合に生じるものであると考えられる。 Note that “swelling” is used synonymously with edema, and is a state in which tissue fluid or lymph fluid is accumulated in cells, cell gaps, or body cavities for some reason, and is found in subcutaneous tissues. In particular, the “swelling” targeted by the present invention is a spontaneous swelling caused by standing or sitting in daily life, and is not restricted, but leakage of bodily fluids from capillaries and collection of bodily fluids by veins and lymphatic system This is considered to occur when the balance of the balance is lost.
本発明のむくみ抑制または改善剤は、当該身体局所、特に下肢部のむくみに対して優れた抑制または改善効果を発揮する。 The swelling suppression or improvement agent of the present invention exerts an excellent suppression or improvement effect on the body local area, particularly swelling of the lower limbs.
(II)むくみ抑制または改善用の経口組成物用添加剤
本発明のむくみ抑制または改善用の経口組成物用添加剤は、黒大豆種皮抽出物、好ましくは可食性の黒大豆種皮抽出物を有効成分とすることを特徴とする。
(II) Additive for oral composition for swelling suppression or improvement The additive for oral composition for swelling suppression or improvement of the present invention is effective for black soybean seed coat extract, preferably edible black soybean seed coat extract It is characterized by being a component.
当該本発明の添加剤は、その有効成分である黒大豆種皮抽出物が有するむくみ抑制または改善作用に基づいて、対象とする経口組成物にむくみ抑制または改善作用を付与するために用いられる添加剤である。また本発明の添加剤は、むくみ抑制または改善作用を有する経口組成物に対して、その作用をさらに強化するためにも用いることができる。 The additive of the present invention is an additive used for imparting swelling or suppressing action to a target oral composition based on the swelling or suppressing action of black soybean seed coat extract which is an active ingredient. It is. The additive of the present invention can also be used to further enhance the action of an oral composition having an action of suppressing or improving swelling.
ここで、本発明が対象とする経口組成物には、人に対して経口的に投与する組成物または人が摂取する組成物、具体的には経口医薬品組成物、経口医薬部外品組成物、及び食品組成物(飲料を含む。以下、同じ)が含まれる。好ましくは食品組成物である。 Here, the oral composition targeted by the present invention includes a composition that is orally administered to a person or a composition that is taken by a person, specifically an oral pharmaceutical composition, an oral quasi-drug composition. And food compositions (including beverages, hereinafter the same). A food composition is preferred.
本発明の添加剤の原料として使用する黒大豆の種類、黒大豆種皮の取得方法、黒大豆種皮抽出物、特に抽出物の好適な一態様である黒大豆種皮酸性抽出物の調製方法は、上記(I)で説明した通りであり、本欄(II)において援用することができる。 The kind of black soybean used as a raw material of the additive of the present invention, the method for obtaining black soybean seed coat, the method for preparing black soybean seed coat acidic extract, which is a preferred embodiment of the black soybean seed coat extract, particularly the extract, As described in (I), it can be incorporated in this column (II).
本発明の添加剤は、可食性の黒大豆種皮抽出物のなかでも、黒大豆種皮から水溶性溶媒にて加温酸性条件下で抽出して得られる抽出物を有効成分とすることが好ましい。 Among the edible black soybean seed coat extracts, the additive of the present invention preferably contains, as an active ingredient, an extract obtained by extraction from black soybean seed coat under a heated acidic condition with a water-soluble solvent.
また本発明の添加剤は、黒大豆種皮を原料として溶媒抽出、好ましくは酸性溶媒抽出により調製される組成物を有効成分とする。 The additive of the present invention contains, as an active ingredient, a composition prepared by solvent extraction, preferably acidic solvent extraction, using black soybean seed coat.
本発明の添加剤は、黒大豆種皮抽出物そのものであってもよいし、また黒大豆種皮抽出物に薬学的にまた食品として許容される従来公知の可食性の担体、賦形剤等を組み合わせて調製されたものであってもよい。本発明の添加剤は、上記経口医薬品、経口医薬部外品、及び/又は飲食物に添加配合して、むくみ抑制または改善用組成物(経口組成物)を調製するために用いられる。このため、その限りにおいて、その形態を特に問わず、上記抽出方法により調製される液剤(エキス形態やシロップを含む)やゼリー剤の形態を有していても、また当該液剤を常法により粉末状または顆粒状に製剤化した散剤、細粒剤、顆粒剤;液剤や散剤または顆粒剤をカプセルに充填したカプセル剤(硬質カプセル剤、軟質カプセル剤)、または粉末または顆粒をさらに打錠して錠剤形態としたものを使用してもよい(固形製剤)。 The additive of the present invention may be a black soybean seed coat extract itself, or a combination of a black soybean seed coat extract and a conventionally known edible carrier, excipient or the like that is pharmaceutically acceptable as a food. May be prepared. The additive of the present invention is used for preparing a composition for suppressing swelling or improving (oral composition) by adding to and blending with the above oral medicine, oral quasi-drug, and / or food and drink. For this reason, as long as the form is not particularly limited, the liquid preparation (including extract form and syrup) and the form of jelly preparation prepared by the above extraction method or jelly preparation may be used in a conventional manner. Powder, fine granule, granule formulated into powder or granule; capsule filled with liquid, powder or granule (hard capsule, soft capsule), or powder or granule What was made into the tablet form may be used (solid preparation).
経口医薬品、経口医薬部外品、及び/又は飲食物に添加配合して用いられる本発明の添加剤の量は、本発明の添加剤を配合することで調製されるむくみ抑制または改善用の経口組成物の一日投与(摂取)が、黒大豆種皮抽出物(乾燥量)の量に換算して、通常40〜160mg程度になるよう割合を挙げることができる。 The amount of the additive of the present invention used by adding to and blended with oral pharmaceuticals, oral quasi-drugs, and / or foods and drinks is the oral for swelling suppression or improvement prepared by blending the additive of the present invention. The ratio can be mentioned so that the daily administration (intake) of the composition is usually about 40 to 160 mg in terms of the amount of black soybean seed coat extract (dry amount).
なお、本発明の添加剤は、上記経口組成物(経口医薬品、経口医薬部外品、及び/又は飲食物)を調製する工程で他の原料とともに原料の一つとして使用されるか、或いは経口組成物を服用(投与または摂取)する際に、当該経口組成物に用事配合して使用することができる。 The additive of the present invention is used as one of raw materials together with other raw materials in the step of preparing the above oral composition (oral medicine, oral quasi-drug, and / or food or drink), or orally. When the composition is taken (administered or ingested), it can be used after being mixed with the oral composition.
以下に実験例を示して本発明をより詳細に説明するが、本発明はこれらに限定されない。なお、下記の実施例において特に言及しない場合は、「部」は重量部を、「%」は重量%を意味するものとする。 Although an experiment example is shown below and this invention is demonstrated in detail, this invention is not limited to these. In the following Examples, “part” means part by weight and “%” means weight% unless otherwise specified.
実験例1 黒大豆種皮抽出物(含水エタノール抽出物)の抗むくみ作用
3名の被験者(被験者A〜C)を対象として、黒大豆種皮の酸性抽出物及び含水エタノール抽出物のそれぞれについて抗むくみ作用を評価した。
Experimental Example 1 Anti-swelling action of black soybean seed coat extract (hydrous ethanol extract) Anti-swelling action for each of three subjects (subjects A to C), acidic extract of black soybean seed coat and hydrous ethanol extract Evaluated.
(1)被験試料の調製
(a)黒大豆種皮の含水エタノール抽出物
黒大豆種皮の含水エタノール抽出物は、下記の方法で調製した。
(1)黒大豆種皮(生)500gを抽出溶媒として40%濃度のエタノール水溶液15Lに浸漬し、40℃に加温しながら90分間撹拌抽出する。
(2)抽出後、黒大豆種皮と液とを固液分離し、液を回収する。
(3)回収した液を遠心分離を行ない、固液分離では取り除けない浮遊固形物を除去する。
(4)得られた抽出液を減圧下で加熱することにより蒸発させ、濃縮する。
(5)得られた濃縮液に、賦形剤としてデキストリンを添加する。
(6) これを加熱殺菌後、乾燥して粉末(合計119.8g、黒大豆種皮抽出物31.9g含有)とし、これを100mgずつカプセル基剤に充填して、被験試料1(1カプセルあたり乾燥粉末100mg含有)とした。
(1) Preparation of test sample (a) Water-containing ethanol extract of black soybean seed coat A water-containing ethanol extract of black soybean seed coat was prepared by the following method.
(1) 500 g of black soybean seed coat (raw) is immersed in 15 L of a 40% ethanol aqueous solution as an extraction solvent, and extracted with stirring for 90 minutes while heating to 40 ° C.
(2) After extraction, the black soybean seed coat and liquid are separated into solid and liquid, and the liquid is recovered.
(3) Centrifuge the collected liquid to remove suspended solids that cannot be removed by solid-liquid separation.
(4) The obtained extract is evaporated by heating under reduced pressure and concentrated.
(5) Add dextrin as an excipient to the concentrated solution.
(6) After heat sterilization, this was dried to a powder (total 119.8 g, containing black soybean seed coat extract 31.9 g), and 100 mg each was filled into the capsule base, and test sample 1 (per capsule) 100 mg of dry powder).
(b)プラセボ
プラセボとして賦形剤(デキストリン)だけをカプセル基剤に充填したカプセル(1カプセルあたりデキストリン100mg含有)を使用した。
(B) Placebo Capsules (containing 100 mg of dextrin per capsule) in which only the excipient (dextrin) was filled in the capsule base were used as placebos.
(2)実験方法
(1)朝9時〜9時半に各被験者の右膝下の体積を測定する。
(2)12時〜13時の間に、上記で調製した被験試料1、またはプラセボを3カプセルずつ経口摂取する。なお、被験試料1には3カプセル(乾燥粉末合計300mg)あたり、黒大豆種皮抽出物が乾燥重量で80mg含まれている。
(3)夕方17時半〜18時に再び各被験者の右膝下下肢部の体積を測定する。
(4)各被験者とも、上記試験を被験試料およびプラセボともに2日間ずつ行った(クロスオ−バ−試験)。
(2) Experimental method
(1) Measure the volume under the right knee of each subject from 9 am to 9:30 am
(2) Between 12 o'clock and 13 o'clock, take 3 capsules of the test sample 1 or the placebo prepared above orally. Test sample 1 contains 80 mg of black soybean seed coat extract by dry weight per 3 capsules (total dry powder of 300 mg).
(3) The volume of the lower leg part of each subject's right knee is again measured from 17:30 to 18:00 in the evening.
(4) For each subject, the above test was conducted for two days for both the test sample and placebo (crossover test).
膝下体積の測定は、足先から膝下までがすべて入る大きさのアクリル製の水槽(タテ30cm×横20cm×高さ60cm)を用いて行った。具体的には、当該水槽に予め深さ45cmまで水を張っておき(総容積22.47L)、その中に右脚を入れ、上昇した水位から右膝下下肢部の体積を求めた。なお、水槽に脚を入れる深さが毎回変わらないように、膝中央部とひかがみに印を付けておき、当該印が水面と一致するようにした。測定は2回ずつ行い、その平均値を求めた。 The measurement of the volume under the knee was performed using an acrylic water tank (vertical 30 cm × width 20 cm × height 60 cm) that is large enough to fit from the toes to the knee. Specifically, the water tank was filled with water up to a depth of 45 cm in advance (total volume 22.47 L), the right leg was put therein, and the volume of the lower leg part of the right knee was determined from the elevated water level. In addition, the center of the knee and the fold were marked so that the depth of putting the leg into the water tank was not changed every time, so that the mark coincided with the water surface. The measurement was performed twice, and the average value was obtained.
(3)実験結果
朝夕の右膝下下肢部の体積(cm3)とその体積差([夕方の体積(cm3)]−[朝の体積(cm3)])の平均を、各被験者毎に示す。
(3) Experimental results The average of the volume (cm 3 ) of the lower limb of the right knee in the morning and evening and the volume difference ([Evening volume (cm 3 )]-[Morning volume (cm 3 )]) for each subject. Show.
この結果から、黒大豆種皮の含水エタノール抽出物(被験試料1)は、経口的摂取によって、下肢部に対して抗むくみ作用を発揮することがわかる。 From this result, it can be seen that the water-containing ethanol extract of black soybean seed coat (test sample 1) exhibits an anti-swelling action on the lower limbs when taken orally.
実験例2 黒大豆種皮抽出物(酸性熱水抽出物)の抗むくみ作用の評価
23〜36才の女性20名(被験者)(実験例1の被験者A〜Cを含む)を対象として、黒大豆種皮抽出物の抗むくみ作用を評価した。
Experimental Example 2 Evaluation of anti-swelling effect of black soybean seed coat extract (acid hot water extract) Black soybeans targeting 20 females (subjects) 23-36 years old (including subjects A to C of Experimental example 1) The anti-swelling action of the seed coat extract was evaluated.
(1)被験試料の調製
黒大豆種皮の酸性熱水抽出物は下記の方法により調製した。
(1)黒大豆種皮(生)500gを抽出溶媒として希硫酸(0.3%w/v)15Lに浸漬し、55〜60℃に加熱しながら20分間撹拌抽出する。
(2)抽出後、黒大豆種皮と液とを固液分離し、液を回収する。
(3)回収した液を遠心分離を行ない、固液分離では取り除けない浮遊固形物を除去する。
(4)得られた抽出液を合成吸着樹脂(セパビーズSP700:三菱化学(株)製)を入れたカラムに投入し、樹脂に吸着させる。
(5)カラム内に残存する硫酸を洗い流すため、カラムに水を通液して樹脂を洗浄する。
(6)カラムに59容量%濃度のアルコ−ル水溶液を通液して、樹脂に吸着されたポリフェノールを溶出させる。
(7)回収した溶出液(アルコール溶液)を減圧下で加熱することにより蒸発させ、濃縮する。
(8)得られた濃縮液に、賦形剤としてデキストリンを添加する。
(9)加熱殺菌する。
(10)加熱殺菌後の濃縮液を噴霧乾燥して粉末(合計42.5g、黒大豆種皮酸性熱水抽出物34g含有)とし、これを100mgずつカプセル基剤に充填して、被験試料2(1カプセルあたり乾燥粉末100mg含有)とした。一方、プラセボとして賦形剤(デキストリン)のみを充填したカプセル(1カプセルあたりデキストリン100mg含有)を用いた。
(1) Preparation of test sample An acidic hot water extract of black soybean seed coat was prepared by the following method.
(1) 500 g of black soybean seed coat (raw) is immersed in 15 L of dilute sulfuric acid (0.3% w / v) as an extraction solvent, and stirred and extracted for 20 minutes while heating to 55-60 ° C.
(2) After extraction, the black soybean seed coat and liquid are separated into solid and liquid, and the liquid is recovered.
(3) Centrifuge the collected liquid to remove suspended solids that cannot be removed by solid-liquid separation.
(4) The obtained extract is put into a column containing a synthetic adsorption resin (Separbeads SP700: manufactured by Mitsubishi Chemical Corporation) and adsorbed on the resin.
(5) In order to wash away the sulfuric acid remaining in the column, the resin is washed by passing water through the column.
(6) A 59% by volume aqueous alcohol solution is passed through the column to elute the polyphenol adsorbed on the resin.
(7) The recovered eluate (alcohol solution) is evaporated by heating under reduced pressure and concentrated.
(8) Add dextrin as an excipient to the concentrated solution.
(9) Sterilize by heating.
(10) The concentrated solution after heat sterilization is spray-dried to obtain a powder (total 42.5 g, containing black soybean seed coat acidic hot water extract 34 g). 100 mg of dry powder per capsule). On the other hand, capsules (containing 100 mg of dextrin per capsule) filled only with excipients (dextrin) were used as placebos.
(2)実験方法
実験例1(2)に記載する方法に従って、20名の被験者に、被験試料2またはプラセボを1カプセルずつ、それぞれ2日間服用してもらい、服用前(朝)と服用後(夕方)とで、右膝下下肢部の体積を比較し、被験試料2の抗むくみ作用を評価した。なお、被験試料2には1カプセル(乾燥粉末合計100mg)あたり、黒大豆種皮酸性熱水抽出物が乾燥重量で80mg含まれている。
(2) Experimental method According to the method described in Experimental Example 1 (2), 20 subjects took 1 capsule each of test sample 2 or placebo for 2 days, before taking (morning) and after taking ( In the evening, the volume of the lower leg part of the right knee was compared, and the anti-swelling action of the test sample 2 was evaluated. Test sample 2 contains 80 mg of black soybean seed coat acidic hot water extract in a dry weight per capsule (100 mg in total of dry powder).
(3)実験結果
(3−1)朝夕の右膝下下肢部の体積(cm3)とその体積差([夕方の体積(cm3)]−[朝の体積(cm3)])の20名の被験者の平均値を表2に示す。
(3) Experimental results (3-1) Volume of right lower leg leg in morning and evening (cm 3 ) and volume difference ([Evening volume (cm 3 )]-[Morning volume (cm 3 )]) 20 persons Table 2 shows the average values of the subjects.
この結果から、被験試料2(黒大豆種皮酸性熱水抽出物)を経口摂取することで、下肢部のむくみが有意に抑制(または改善)することがわかる。つまりこのことから、黒大豆種皮酸性熱水抽出物には、下肢部のむくみを抑制または改善する作用(抗むくみ作用)があることが判明した。 From this result, it is understood that swelling of the lower limbs is significantly suppressed (or improved) by ingesting test sample 2 (black soybean seed coat acidic hot water extract). That is, from this, it was found that black soybean seed coat acidic hot water extract has an action to suppress or improve swelling of the lower limbs (anti-swelling action).
(3−2)また、実験例1で実験した被験者A〜Cに対して、被験試料2(黒大豆種皮酸性熱水抽出物)を経口摂取させた結果を表3に示す。 (3-2) Table 3 shows the results of oral intake of the test sample 2 (black soybean seed coat acidic hot water extract) to the subjects A to C tested in Experimental Example 1.
この結果から、黒大豆種皮の含水エタノール抽出物(被験試料1)よりも、被験試料2(黒大豆種皮酸性熱水抽出物)のほうが抗むくみ作用に優れていることがわかる。 From this result, it can be seen that test sample 2 (black soybean seed coat acidic hot water extract) is superior in anti-swelling action than water-containing ethanol extract of black soybean seed coat (test sample 1).
実験例3 黒大豆種皮酸性熱水抽出物の抗むくみ作用の評価
23〜30才の女性3名(被験者D、E及びF)を対象として、黒大豆種皮酸性熱水抽出物の抗むくみ作用の用量依存性を評価した。
Experimental Example 3 Evaluation of anti-swelling action of black soybean seed coat acid hot water extract The anti-swelling action of black soybean seed coat acid hot water extract was studied for three women (subjects D, E and F) aged 23 to 30 years. Dose dependence was evaluated.
(1)実験方法
実験例2で調製した黒大豆種皮酸性熱水抽出物含有乾燥粉末を50mg(黒大豆種皮酸性熱水抽出物40mg含有)、または100mg(黒大豆種皮酸性熱水抽出物80mg含有)、または200mg(黒大豆種皮酸性熱水抽出物160mg含有)を、実験例1と同じ方法で3名の被験者に経口摂取してもらい(昼間)、朝夕に右膝下下肢部の体積を測定して(2日間、2回ずつ測定)、朝夕の下肢部体積(cm3)の差([夕方の体積(cm3)]−[朝の体積(cm3)])から、当該被験試料のむくみ抑制または改善効果を調べた。なお、同被験者に、別の日に、被験試料を摂取することなく、朝夕に右膝下下肢部の体積を測定してもらい(2日間、2回ずつ測定)、この体積差([夕方の体積(cm3)]−[朝の体積(cm3)])をコントロ−ル値とした。
(1) Experimental method 50 mg of black soybean seed coat acidic hot water extract-containing dry powder prepared in Experimental Example 2 (containing 40 mg of black soybean seed coat acidic hot water extract) or 100 mg (containing 80 mg of black soybean seed coat acidic hot water extract) ), Or 200 mg (containing 160 mg of black soybean seed coat acidic hot water extract) orally by 3 subjects in the same manner as in Experimental Example 1 (in the daytime), and in the morning and evening, measure the volume of the lower leg of the right knee. (Measured twice each for 2 days), the swelling of the test sample from the difference between the morning and evening lower limb volume (cm 3 ) ([evening volume (cm 3 )]-[morning volume (cm 3 )]) The suppression or improvement effect was investigated. In addition, the same subject was asked to measure the volume of the lower leg part of the right knee in the morning and evening without taking the test sample on another day (measured twice for two days), and this volume difference ([evening volume) (Cm 3 )]-[morning volume (cm 3 )]) was taken as the control value.
(2)実験結果
表4に、朝夕の右膝下下肢部の体積差(cm3)の平均値を各被験者毎に示す。
(2) Experimental results Table 4 shows the average value of the volume difference (cm 3 ) of the lower leg part of the right knee in the morning and evening for each subject.
この結果から、被験試料(黒大豆種皮抽出物)を経口摂取することで、下肢部のむくみが有意に抑制(または改善)することがわかる。用量の範囲としては、少なくとも今回検討した黒大豆種皮酸性熱水抽出物によれば、乾燥重量として40mg〜160mgの範囲において、本発明の所望の効果が得られることがわかる。 From this result, it is understood that swelling of the lower limbs is significantly suppressed (or improved) by ingesting the test sample (black soybean seed coat extract). As for the dose range, it can be seen that at least the black soybean seed coat acidic hot water extract examined this time can achieve the desired effect of the present invention in the range of 40 mg to 160 mg as the dry weight.
黒大豆種皮抽出物の処方例を以下に示す。
処方例1 ソフトカプセル
下記の原料を用いて、定法に従ってソフトカプセルを調製した。なお、黒大豆種皮抽出物として、実験例2(1)の方法に従って調製した黒大豆種皮の酸性熱水抽出物を用いた。
植物油脂:158.6mg
ゼラチン:135.2mg
黒大豆種皮抽出物:100mg
グリセリン:30.2mg
レシチン:30mg
ミツロウ:26mg
ビタミンE:20mg。
A prescription example of black soybean seed coat extract is shown below.
Formulation Example 1 Soft Capsules Soft capsules were prepared according to a conventional method using the following raw materials. As the black soybean seed coat extract, an acidic hot water extract of black soybean seed coat prepared according to the method of Experimental Example 2 (1) was used.
Vegetable oil and fat: 158.6mg
Gelatin: 135.2 mg
Black soybean seed coat extract: 100mg
Glycerin: 30.2mg
Lecithin: 30mg
Beeswax: 26mg
Vitamin E: 20 mg.
処方例2 錠剤
下記の原料を用いて、定法に従って錠剤を調製した。なお、黒大豆種皮抽出物として、実施例1(1)の方法に従って調製した黒大豆種皮の含水エタノール抽出物を用いた。
デキストリン:179.69mg
黒大豆種皮抽出物:100mg
還元水あめ:28.56mg
結晶セルロース:26.51mg
ステアリン酸カルシウム:5.25mg
微粒二酸化ケイ素:5.25mg
ヒドロキシプロピルセルロース:4.77mg。
Formulation Example 2 Tablet Tablets were prepared according to a conventional method using the following raw materials. As the black soybean seed coat extract, a water-containing ethanol extract of black soybean seed coat prepared according to the method of Example 1 (1) was used.
Dextrin: 179.69 mg
Black soybean seed coat extract: 100mg
Reduced water candy: 28.56mg
Crystalline cellulose: 26.51 mg
Calcium stearate: 5.25mg
Fine silicon dioxide: 5.25mg
Hydroxypropyl cellulose: 4.77 mg.
処方例3 個包装スティックゼリー
下記の原料を用いて、定法に従って個包装スティックゼリーを調製した。なお、黒大豆種皮抽出物として、実施例1(1)の方法に従って調製した黒大豆種皮の含水エタノール抽出物を用いた。
希少糖含有シロップ:1000mg
黒大豆種皮抽出物:100mg
ゲル化剤(増粘多糖類):100mg
甘味料(キシリトール、スクラロース、ソーマチン、アセスルファムカリウム):70mg
香料:20mg
水:8710mg
Formulation Example 3 Individual Packaging Stick Jelly An individual packaging stick jelly was prepared according to a conventional method using the following raw materials. As the black soybean seed coat extract, a water-containing ethanol extract of black soybean seed coat prepared according to the method of Example 1 (1) was used.
Rare sugar-containing syrup: 1000mg
Black soybean seed coat extract: 100mg
Gelling agent (thickening polysaccharide): 100 mg
Sweetener (xylitol, sucralose, thaumatin, acesulfame potassium): 70mg
Fragrance: 20mg
Water: 8710mg
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014211330A JP6444688B2 (en) | 2014-10-16 | 2014-10-16 | Swelling suppression or improvement agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014211330A JP6444688B2 (en) | 2014-10-16 | 2014-10-16 | Swelling suppression or improvement agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016079124A JP2016079124A (en) | 2016-05-16 |
JP6444688B2 true JP6444688B2 (en) | 2018-12-26 |
Family
ID=55955875
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014211330A Active JP6444688B2 (en) | 2014-10-16 | 2014-10-16 | Swelling suppression or improvement agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6444688B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6417576B2 (en) * | 2016-06-06 | 2018-11-07 | チャーサイアー バイオテクノロジー コーポレイションCharsire Biotechnology Corp. | Soybean seed extract, method for producing the soybean seed extract and use thereof |
US10543243B2 (en) | 2016-06-06 | 2020-01-28 | Charsire Biotechnology Corp. | Soybeam seed extract, method for producing the same and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003095940A (en) * | 2001-09-25 | 2003-04-03 | Ichimaru Pharcos Co Ltd | Diuretic composition |
KR100526760B1 (en) * | 2003-09-05 | 2005-11-08 | 김현석 | An oriental herb extracts composition having detoxification effect on the nicotine and dioxin |
JP2006290742A (en) * | 2005-04-05 | 2006-10-26 | Kyoei Kagaku Kogyo Kk | Antiaging cosmetic |
CN1935000A (en) * | 2005-09-23 | 2007-03-28 | 杨朝生 | Preparation method of black bean tea |
KR101199209B1 (en) * | 2008-08-01 | 2012-11-07 | (주)아모레퍼시픽 | Cosmetic composition containing fermented extracts with salt of natural materials |
-
2014
- 2014-10-16 JP JP2014211330A patent/JP6444688B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016079124A (en) | 2016-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4669920B2 (en) | Functional material that suppresses blood glucose rise and blood pressure rise | |
JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
JP4879741B2 (en) | Body fat reducing agent | |
JP2005154432A (en) | Treated material of acerola containing polyphenol and/or vitamin c | |
JPWO2014010656A1 (en) | Excellent promoter for lowering blood alcohol levels | |
JP6444688B2 (en) | Swelling suppression or improvement agent | |
JP2008266223A (en) | Formulation for ameliorating excessive sensitivity to cold | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR102348044B1 (en) | Composition for preventing, improving or treating burn out syndrome | |
KR101765246B1 (en) | Composition for preventing and improving sex hormone-related disease | |
CN111297918A (en) | Composition of EGCG and cordyceps militaris extract and preparation method and application thereof | |
WO2005094858A1 (en) | Antidiabetic composition | |
KR101731859B1 (en) | A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
EP1583547A1 (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
US20240024399A1 (en) | Bioactive compounds extraction from plant matters of silybum marianum and usage | |
JP2005089374A (en) | Food and drink having function for preventing increase in blood glucose level | |
KR100678562B1 (en) | Use of Bamboo Extract for Lowering Blood Pressure | |
JP6615200B2 (en) | Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil, and formulation obtained by formulating the composition | |
KR20190142672A (en) | Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract | |
JP6321908B2 (en) | Oral composition for swelling treatment | |
KR20170005873A (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
KR20170011236A (en) | Pharmaceutical composition comprising artemisia sp extract or eupatilin for prevention or treatment of ischemia reperfusion injury | |
KR20230119422A (en) | Composition for the prevention and treatment of inflammatory edema comprising Phaseolus angularis Wight extract as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180509 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6444688 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |